Companies › Lomond Therapeutics Holdings
2 active drug programs in 3 registered trials: 3 Phase 1; Other, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lonitoclax (ZE50-0134) BCL2 inhibitor | BCL2 | Phase 1 | Acute Myeloid Leukemia; CLL / SLL | Dec 2026 |
| ZE46-0134 FLT3 inhibitor; spliceosome modulator | – | Phase 1 | AML With Gene Mutations | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07303660 | Lonitoclax (ZE50-0134) | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT06366789 | ZE46-0134 | Phase 1 | AML With Gene Mutations | Other | Dec 2027 |
| NCT06708897 | Lonitoclax (ZE50-0134) | Phase 1 | CLL / SLL | Oncology | Jan 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.